Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction

Circulation

Volumn 110, Issue 21, 2004, Pages 3306-3312

  Kawakami, Rika ^a   Saito, Yoshihiko ^a,b   Kishimoto, Ichiro ^a,c   Harada, Masaki ^a   Kuwahara, Koichiro ^a   Takahashi, Nobuki ^a   Nakagawa, Yasuaki ^a   Nakanishi, Michio ^a   Tanimoto, Keiji ^a   Usami, Satoru ^a   Yasuno, Shinji ^a   Kinoshita, Hideyuki ^a   Chusho, Hideki ^a   Tamura, Naohisa ^a   Ogawa, Yoshihiro ^a   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Metalloproteinases; Myocardial infarction; Natriuretic peptides; Neutrophils; Remodeling

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DOXYCYCLINE; GELATINASE A; GELATINASE B; NESIRITIDE;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BNP GENE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE; HEART PROTECTION; HEART VENTRICLE REMODELING; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; MMP 9 GENE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; WOUND HEALING; ZYMOGRAPHY;

ANIMALS; CHEMOTAXIS, LEUKOCYTE; DOXYCYCLINE; ENZYME ACTIVATION; ENZYME INDUCTION; GENE EXPRESSION PROFILING; HEART VENTRICLES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NEUTROPHILS; PEROXIDASE; RECOMBINANT FUSION PROTEINS;

EID: 20844452374     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000147829.78357.C5     Document Type: Article

References (32)

1. De Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science. 1985;230:767-770.
2. Rosenzweig A, Seidman CE. Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem. 1991;60:229-255.
3. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-1412.
4. Mukoyama M, Nakao K, Saito Y, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med. 1990;323:757-758.
5. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993;88:82-91.
6. Yamamoto K, Burnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988-994.
7. Nagaya N, Goto Y, Nishikimi T, et al. Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction. Clin Sci. 1999;96:129-136.
8. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA. 2000;97:4239-4244.
9. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999;34:155-162.
10. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
11. Holtwick R, van Eickels M, Skryabin BV, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest. 2003;111:1399-1407.
12. Molkentin J. A friend within the heart: natriuretic peptide receptor signaling. J Clin Invest. 2003;111:1275-1277.
13. Ogawa Y, Itoh H, Tamura N, et al. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest. 1994;93:1911-1921.
14. Chusho H, Ogawa Y, Tamura N, et al. Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways. Endocrinology. 2000;141:3807-3813.
15. Creemers E, Cleutjens J, Smits J, et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol. 2000;156:1865-1873.
16. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142.
17. Michael LH, Entman ML, Hartley CJ, et al. Myocardial ischemia and reperfusion: a murine model. Am J Physiol. 1995;269:H2147-H2154.
18. Patten RD, Aronovitz MJ, Deras-Mejia L, et al. Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol. 1998;274: H1812-H1820.
19. Ichihara S, Senbonmatsu T, Price E Jr, et al. Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation. 2002;106:2244-2249.
20. Izumi T, Saito Y, Kishimoto I, et al. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest. 2001;108:203-213.
21. Silvestre JS, Mallat Z, Tamarat R, et al. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. Circ Res. 2001;89:259-264.
22. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res. 2002;91:845-851.
23. Fujimura M, Gasche Y, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 1999;842:92-100.
24. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003;108:1395-1403.
25. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin- angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
26. Butt RP, Laurent GJ, Bishop JE. Mechanical load and polypeptide growth factors stimulate cardiac fibroblast activity. Ann N Y Acad Sci. 1995;752:387-393.
27. Cleutjens JP, Verluyten MJ, Smiths JF, et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147:325-338.
28. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738-746.
29. Etoh T, Joffs C, Deschamps A, et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol. 2001;281:H987-H994.
30. Tao ZY, Cavasin MA, Yang F, et al. Temporal changes in matrix metalloproteinase expression and inflammatory response associated with cardiac rupture after myocardial infarction in mice. Life Sci. 2004;74:1561-1572.
31. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
32. Elferink JG, De Koster BM. Atrial natriuretic factor stimulates migration by human neutrophils. Eur J Pharmacol. 1995;288:335-340.